Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Wino115on Dec 20, 2021 1:04pm
127 Views
Post# 34247378

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Omicron

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:OmicronI'm not that worried as Paxlovid is on it's way in 2 months. It cuts the risk of hospitalization for anyone by 90% and it is supposedly variant agnostic given how it works, which is different from the vaccines that stimulate your immune system.  They are evidently ramping up production so it will be available in 2 months time given it's a very complex manufacturing process. 

So by Feb, it will just be a case of you feeling bad, take a test early, and take a course of anti-viral pills for a couple of weeks.  As long as you figure it out early, vaccinated or not, you turn it into a treatable virus.  At worse, we're in for 2 months of this.  I can say that in NYC, it hasn't really stopped anything as any large event was only for vaccinated anyway.  We'll probably get more zooming and less in-person things, but I don't think it will shut stuff down like before, especially with the upcoming treatment.   It's way more effective than Mercks, which will now fall by the wayside.



qwerty22 wrote:


 

qwerty22 wrote:

 

 

 

qwerty22 wrote:

 

Ghoulish!
positive = many will die

 

jfm1330 wrote: I also disagree and the unpredicatability. The emergence of a variant like omicron was very predicatable, and you want another prediction? There will be another variant that will totally escape the protection of actual vaccines.

The only possible positive aspect of omicron is that it is so contagious, that so many non vaccinated people will get it, and many will die because of it, but so many unvaccinated will get it, that this will boost collective immunity for a while, until the next variant that will escape that immunity.

 

 

jfm1330 wrote: Out of a recent study made in the UK, there is no evidence omicron is less virulent than delta. This early impression of lower virulence came from South Africa where the population involved was much younger. What I heard from virologists here in Quebec is that omicron is very likely to be as virulent as delta, but much more contagious, but again, the main problem is for the unvaccinated (two or three doses). Vaccine will not offer a great protection against omicron infection, but still a great protection against severe illness, hospitalization and death.

https://www.cnbc.com/2021/12/17/no-evidence-that-covid-omicron-variant-less-severe-than-delta-uk-study.html
 


<< Previous
Bullboard Posts
Next >>